Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226494 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
A Phase 1 study of Glioma, Malignant, sponsored by NanoPharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05226494: Recruiting Phase 1 study of Glioma, Malignant, sponsored by NanoPharmaceuticals.
NCT05226494 is a Phase 1 study of Glioma, Malignant that is actively recruiting participants, run by NanoPharmaceuticals. The registered enrollment target is 34 participants, below the 62-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05226494, a Phase 1 study of Glioma, Malignant, is actively recruiting participants, sponsored by NanoPharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.
Primary Outcome
Determined by the number of Treatment-Emergent Adverse Events, including Dose-Limiting Toxicities per patient.
Conditions Studied
Interventions
- DRUG fb-PMT
Study Locations (1)
Connecticut
- Smilow Cancer Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT05226494 shows while recruiting
NCT05226494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 62-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Glioma, Malignant appearing as the primary indexed condition, and to 1 intervention - of which fb-PMT is the first listed.
NCT05226494 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05226494 about?
NCT05226494 is a clinical study titled "Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma". Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively tran...
What is the current status of trial NCT05226494?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2022-06-23. Estimated completion is 2027-10.
What conditions does trial NCT05226494 study?
This clinical trial studies the following conditions: Glioma, Malignant.
What interventions are being tested in trial NCT05226494?
The interventions under investigation include: fb-PMT (DRUG).
Who is sponsoring clinical trial NCT05226494?
This trial is sponsored by NanoPharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05226494 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma, Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05226494's enrollment target sits among peer trials
34 7th of 19 higher than 13 of 19 other Glioma, Malignant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma, Malignant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
RECRUITING · Phase 1
-
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using 18F-TRX
RECRUITING · Phase 1
-
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI